← All MEPs

Andris Ameriks

European Parliament · 🇱🇻 Latvia · former MEP

Term: from 18 July 2019 to 25 April 2024

Participation in roll-call votes

84 % of the 1,811 roll-call votes held during their term: took part in the vote (for, against or abstention)

Participation month by month

0 % 50 % 100 % July 2019 : participation 100 % (1 / 1), presence 100 % (1 / 1) 2019 September 2019 : participation 100 % (5 / 5), presence 100 % (5 / 5) October 2019 : participation 53 % (10 / 19), presence 53 % (10 / 19) November 2019 : participation 94 % (17 / 18), presence 94 % (17 / 18) December 2019 : participation 83 % (5 / 6), presence 83 % (5 / 6) January 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) 2020 February 2020 : participation 0 % (0 / 8), presence 0 % (0 / 8) May 2020 : participation 100 % (54 / 54), presence 100 % (54 / 54) June 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) July 2020 : participation 95 % (18 / 19), presence 95 % (18 / 19) September 2020 : participation 100 % (24 / 24), presence 100 % (24 / 24) October 2020 : participation 100 % (37 / 37), presence 100 % (37 / 37) November 2020 : participation 100 % (32 / 32), presence 100 % (32 / 32) December 2020 : participation 100 % (30 / 30), presence 100 % (30 / 30) January 2021 : participation 100 % (23 / 23), presence 100 % (23 / 23) 2021 February 2021 : participation 100 % (21 / 21), presence 100 % (21 / 21) March 2021 : participation 81 % (25 / 31), presence 81 % (25 / 31) April 2021 : participation 99 % (80 / 81), presence 99 % (80 / 81) May 2021 : participation 100 % (26 / 26), presence 100 % (26 / 26) June 2021 : participation 90 % (26 / 29), presence 90 % (26 / 29) July 2021 : participation 96 % (26 / 27), presence 96 % (26 / 27) September 2021 : participation 100 % (19 / 19), presence 100 % (19 / 19) October 2021 : participation 86 % (36 / 42), presence 86 % (36 / 42) November 2021 : participation 100 % (27 / 27), presence 100 % (27 / 27) December 2021 : participation 93 % (27 / 29), presence 93 % (27 / 29) January 2022 : participation 100 % (7 / 7), presence 100 % (7 / 7) 2022 February 2022 : participation 90 % (26 / 29), presence 90 % (26 / 29) March 2022 : participation 100 % (37 / 37), presence 100 % (37 / 37) April 2022 : participation 0 % (0 / 22), presence 0 % (0 / 22) May 2022 : participation 97 % (85 / 88), presence 97 % (85 / 88) June 2022 : participation 85 % (39 / 46), presence 85 % (39 / 46) July 2022 : participation 100 % (31 / 31), presence 100 % (31 / 31) September 2022 : participation 100 % (25 / 25), presence 100 % (25 / 25) October 2022 : participation 97 % (31 / 32), presence 97 % (31 / 32) November 2022 : participation 100 % (38 / 38), presence 100 % (38 / 38) December 2022 : participation 94 % (17 / 18), presence 94 % (17 / 18) January 2023 : participation 0 % (0 / 16), presence 0 % (0 / 16) 2023 February 2023 : participation 97 % (28 / 29), presence 97 % (28 / 29) March 2023 : participation 79 % (23 / 29), presence 79 % (23 / 29) April 2023 : participation 92 % (22 / 24), presence 92 % (22 / 24) May 2023 : participation 96 % (89 / 93), presence 96 % (89 / 93) June 2023 : participation 48 % (19 / 40), presence 48 % (19 / 40) July 2023 : participation 98 % (39 / 40), presence 98 % (39 / 40) September 2023 : participation 96 % (26 / 27), presence 96 % (26 / 27) October 2023 : participation 55 % (22 / 40), presence 55 % (22 / 40) November 2023 : participation 77 % (41 / 53), presence 77 % (41 / 53) December 2023 : participation 100 % (40 / 40), presence 100 % (40 / 40) January 2024 : participation 0 % (0 / 49), presence 0 % (0 / 49) 2024 February 2024 : participation 70 % (44 / 63), presence 70 % (44 / 63) March 2024 : participation 98 % (49 / 50), presence 98 % (49 / 50) April 2024 : participation 71 % (152 / 213), presence 71 % (152 / 213)

Their votes

1,811 votes

DateTextResultTheir vote
Commission Implementing Regulation (EU) 2019/707 of 7 May 2019 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances alpha-cypermethrin, beflubutamid, benalaxyl, benthiavalicarb, bifenazate, boscalid, bromoxynil, captan, cyazofamid, desmedipham, dimethoate, dimethomorph, diuron, ethephon, etoxazole, famoxadone, fenamiphos, flumioxazine, fluoxastrobin, folpet, foramsulfuron, formetanate, metalaxyl-m, methiocarb, metribuzin, milbemectin, Paecilomyces lilacinus strain 251, phenmedipham, phosmet, pirimiphos-methyl, propamocarb, prothioconazole, s-metolachlor and tebuconazole For
Employment and social policies of the euro area For
Foreign electoral interference and disinformation in national and European democratic processes For
Flexibility Instrument: adjustments to the amounts mobilised for 2019 to be used for migration, refugee inflows and security threats Against
Amending budget 4/2019: reduction of commitment and payment appropriations in line with updated needs of expenditure and update of revenue (own resources) For
The importance of European remembrance for the future of Europe For
Iran, notably the situation of women’s rights defenders and imprisoned EU dual nationals For
The state of implementation of the Union’s anti-money laundering legislation For
The state of play of the UK’s withdrawal from the European Union For
Amending budget 2/2019: Horizon 2020 and Erasmus+ For
The situation in Venezuela For

Rows per page: 20 40 100 200